Omega-3 (DHA/EPA) for ALS
Also known as: DHA, EPA, Fish oil, Docosahexaenoic acid, Eicosapentaenoic acid
DHA is the predominant fatty acid in neuronal membranes, and its depletion may accelerate motor neuron degeneration in ALS.
Mechanism of Action
DHA maintains neuronal membrane fluidity, enhances BDNF signaling, and generates specialized pro-resolving mediators (SPMs: resolvins, protectins, maresins) that resolve neuroinflammation. EPA reduces pro-inflammatory prostaglandin/leukotriene production.
General mechanism: Essential fatty acids. Neuronal membrane component, SPM precursor, NF-κB inhibitor, anti-cachexia, BDNF enhancer.
Current Evidence
Epidemiological data suggests higher omega-3 intake associated with reduced ALS risk. No definitive clinical trials. Biomarker studies show reduced inflammatory markers.
Clinical Status: Epidemiological support. No ALS-specific clinical trials completed.
Safety Profile
Very safe. Fishy aftertaste. Mild GI effects. Bleeding risk at very high doses. Monitor with anticoagulants.
Key Research Questions
- Can high-dose omega-3 generate sufficient SPMs for ALS neuroinflammation resolution?
- Does pre-symptomatic omega-3 supplementation reduce ALS risk?